1398P Real-life progression (PD) pattern of EGFR mutant advanced non-small cell lung cancer (aNSCLC) patients (pts) receiving systemic therapy after first- or second-generation tyrosine kinase inhibitor (1-2 gen TKI)

A Dal Maso,E Scoccia,G Pasello,P.F Conte,L Bonanno,S Indraccolo,M Lorenzi,S Frega,V Polo,A Del Conte,V Guarneri,D Scattolin,F Calabrese,A Ferro

doi:10.1016/j.annonc.2020.08.1712

1398P Real-life progression (PD) pattern of EGFR mutant advanced non-small cell lung cancer (aNSCLC) patients (pts) receiving systemic therapy after first- or second-generation tyrosine kinase inhibitor (1-2 gen TKI)

A Dal Maso, E Scoccia + Show 12 more

Open Access

https://doi.org/10.1016/j.annonc.2020.08.1712

Copy DOI

Journal: Annals of oncology : official journal of the European Society for Medical Oncology	Publication Date: Sep 1, 2020
License type: publisher-specific-oa

Affiliation: University of Padua, Istituto Oncologico Veneto, Ca' Foncello Hospital

#Mutant Advanced Non-small Cell Lung #EGFR Mutant Advanced Non-small Cell + Show 8 more

Abstract
Full-Text PDF
Similar Papers

Abstract

1398P Real-life progression (PD) pattern of EGFR mutant advanced non-small cell lung cancer (aNSCLC) patients (pts) receiving systemic therapy after first- or second-generation tyrosine kinase inhibitor (1-2 gen TKI)

Full Text